Meuwly Marion, Chuard Christian
Service de médecine interne, Hôpital fribourgeois, 1708 Fribourg.
Service d'infectiologie, Hôpital fribourgeois, 1708 Fribourg.
Rev Med Suisse. 2022 Oct 12;18(799):1896-1899. doi: 10.53738/REVMED.2022.18.799.1896.
In 2021, the European and American Infectious Diseases Societies published new guidelines for the treatment of Clostridiodes difficile colitis. They have opted for a change in practice with fidaxomicin being recommended as the first line of treatment, and vancomycin as a second choice. Metronidazole remains recommended only in cases where other treatments are not available. These choices have not been endorsed by the Swiss Infectious Diseases Society, which still proposes metronidazole as first-line treatment. As a matter of fact, this inexpensive treatment still presents a satisfactory efficacy on the strains of Clostridoides difficile found in Switzerland in the context of patients without risk factors and with low probability of relapse.
2021年，欧美传染病学会发布了艰难梭菌结肠炎治疗的新指南。他们选择改变治疗方案，推荐非达霉素作为一线治疗药物，万古霉素作为二线选择。仅在无法采用其他治疗方法的情况下，仍推荐使用甲硝唑。这些选择未得到瑞士传染病学会的认可，该学会仍提议将甲硝唑作为一线治疗药物。事实上，这种价格低廉的治疗方法对于瑞士无风险因素且复发可能性低的患者体内发现的艰难梭菌菌株仍具有令人满意的疗效。
